Lactic acid bacteria and use thereof
US-11554146-B2 · Jan 17, 2023 · US
Lactic acid bacteria and use thereof
US12036253B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12036253-B2 |
| Application number | US-202218065497-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 13, 2022 |
| Priority date | Nov 2, 2017 |
| Publication date | Jul 16, 2024 |
| Grant date | Jul 16, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to Lactobacillus plantarum NK3 and Bifidobacterium longum NK49, which are novel lactic acid bacteria and, more particularly, to a composition comprising novel lactic acid bacteria useful for prevention and treatment of inflammatory diseases.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treating an inflammatory disease comprising administering to a mammalian subject having a symptom of the disease an effective amount of Lactobacillus plantarum NK3 having the accession number KCCM12089P, wherein said inflammatory disease is colitis or vaginitis. 2. The method of claim 1 , wherein the Lactobacillus plantarum NK3 having the accession number KCCM12089P comprises the 16S rDNA sequence of SEQ ID NO: 1. 3. The method of claim 1 , wherein the Lactobacillus plantarum NK3 having the accession number KCCM12089P is a live bacterial cell thereof or a dead bacterial cell thereof. 4. The method of claim 1 , wherein the said inflammatory disease is colitis and said administering is oral administering. 5. The method of claim 1 , wherein the said inflammatory disease is vaginitis and said administering is oral or intravaginal administering. 6. The method of claim 1 , wherein the effective amount is 1×10 2 to 1×10 11 CFU/kg a day.
Assignees
Inventors
Classifications
- C12N1/20Primary
Bacteria; Culture media therefor · CPC title
for osteoporosis · CPC title
Antidepressants · CPC title
Anorexiants; Antiobesity agents · CPC title
Probiotics · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12036253B2 cover?
- The present invention relates to Lactobacillus plantarum NK3 and Bifidobacterium longum NK49, which are novel lactic acid bacteria and, more particularly, to a composition comprising novel lactic acid bacteria useful for prevention and treatment of inflammatory diseases.
- Who is the assignee on this patent?
- Univ Industry Cooperation Group Kyung Hee Univ, Navipharm Co Ltd
- What technology area does this patent fall under?
- Primary CPC classification C12N1/20. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jul 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).